Tilarginine

Drug Profile

Tilarginine

Alternative Names: 546C88; ANO-1020; BW546C88; L-NMMA; N-Monomethyl-arginine; NMA; TAI

Latest Information Update: 03 Sep 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell Research Foundation; M. D. Anderson Cancer Center
  • Developer Arginox Pharmaceuticals
  • Class Antihypotensives; Basic amino acids; Diamino amino acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiogenic shock
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiogenic shock; Hypotension; Kidney disorders; Rheumatoid arthritis; Septic shock; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Nov 2006 Discontinued - Phase-II for Hypotension in United Kingdom (unspecified route)
  • 17 Nov 2006 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top